May 16, 2022
Amylyx Pharmaceuticals Announces Publication of Data Showing Randomization to AMX0035 Prolonged Tracheostomy/Ventilation-free Survival and Reduced Occurrence of First Hospitalization
May 12, 2022
Amylyx Pharmaceuticals Reports First Quarter 2022 Financial Results
May 5, 2022
Amylyx Pharmaceuticals Announces Publication of New CENTAUR Trial Analyses Further Demonstrating Significant Survival Benefit with AMX0035 in People with ALS
April 2, 2022
Amylyx Pharmaceuticals Announces Oral Presentation of Safety and Tolerability Data on AMX0035 from Clinical Trials at 2022 American Academy of Neurology Annual Meeting
March 30, 2022
Amylyx Pharmaceuticals Reports Full Year 2021 Financial Results
March 30, 2022
Amylyx Pharmaceuticals Announces Outcome of FDA Advisory Committee Meeting on AMX0035 for the Treatment of ALS
March 30, 2022
Amylyx Pharmaceuticals Stock Trading Halted Today
March 28, 2022
Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
March 18, 2022
Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
February 25, 2022
Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
February 23, 2022
Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel
February 16, 2022
Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
February 10, 2022
Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 3, 2022
The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes for Canadians Living with ALS
January 6, 2022
Amylyx Pharmaceuticals Announces Pricing of Upsized Initial Public Offering of Common Stock
January 4, 2022
Amylyx Pharmaceuticals Submits Marketing Authorization Application (MAA) for AMX0035 for the Treatment of ALS
January 3, 2022
Amylyx Pharmaceuticals Announces Launch of Initial Public Offering